Wave Life Sciences Ltd.

How big is Wave Life Sciences Ltd.?

As of Jun 18, Wave Life Sciences Ltd. has a market capitalization of 1,015.74 million, with net sales of 104.94 million and a net profit of -112.33 million over the latest four quarters. The balance sheet shows shareholder's funds of 217.39 million and total assets of 352.21 million.

As of Jun 18, Wave Life Sciences Ltd. has a market capitalization of 1,015.74 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 104.94 million for the latest four quarters, while the net profit for the same period was -112.33 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 217.39 million and total assets of 352.21 million.

What does Wave Life Sciences Ltd. do?

WAVE Life Sciences Ltd. is a genetic medicines company focused on developing nucleic acid therapeutics for genetically defined diseases. As of March 2025, it reported net sales of $9 million and a net loss of $47 million, with a market cap of approximately $1.02 billion.

Overview: <BR>WAVE Life Sciences Ltd. is a genetic medicines company in the Pharmaceuticals & Biotechnology industry, focusing on developing nucleic acid therapeutic candidates for genetically defined diseases.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -47 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,015.74 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.31 <BR>Return on Equity: -62.52% <BR>Price to Book: 5.65 <BR><BR>Contact Details: <BR>Address: 7 Straits View, #12-00, Marina One East Tower None : 018936 <BR>Tel: ['65 6 2363388', '1 617 9494827'] <BR>Website: https://www.wavelifesciences.com/

Should I buy, sell or hold Wave Life Sciences Ltd.?

Who are in the management team of Wave Life Sciences Ltd.?

As of March 2022, the management team of Wave Life Sciences Ltd. includes CEO Dr. Paul Bolno and Independent Chairman Mr. Christian Henry, along with several independent directors: Dr. Mark Corrigan, Dr. Peter Kolchinsky, Mr. Koji Miura, and Mr. Adrian Rawcliffe, as well as Director Dr. Gregory Verdine.

As of March 2022, the management team of Wave Life Sciences Ltd. includes the following individuals:<BR><BR>- Mr. Christian Henry, who serves as the Independent Chairman of the Board.<BR>- Dr. Paul Bolno, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Gregory Verdine, who is a Director.<BR>- Dr. Mark Corrigan, who is an Independent Director.<BR>- Dr. Peter Kolchinsky, who is also an Independent Director.<BR>- Mr. Koji Miura, who serves as an Independent Director.<BR>- Mr. Adrian Rawcliffe, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Dr. Paul Bolno holding the key position of CEO.

Is Wave Life Sciences Ltd. overvalued or undervalued?

As of March 16, 2017, Wave Life Sciences Ltd. is considered risky and overvalued due to a high Price to Book Value of 6.19, negative EV to EBIT and EV to EBITDA ratios, a troubling ROE of -62.52%, and poor long-term performance despite a positive one-year stock return.

As of 16 March 2017, the valuation grade for Wave Life Sciences Ltd. moved from does not qualify to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its high Price to Book Value of 6.19 and negative EV to EBIT and EV to EBITDA ratios of -6.98 and -7.50, respectively. Additionally, the Return on Equity (ROE) stands at a concerning -62.52%, reflecting significant losses.<BR><BR>In comparison to its peers, Wave Life Sciences Ltd. has a less favorable EV to EBITDA ratio than Kymera Therapeutics, Inc. at -8.0367 and Adaptive Biotechnologies Corp. at -18.0891, both of which also carry a risky valuation. Despite a positive one-year stock return of 27.24%, which outperformed the S&P 500's 17.14%, the longer-term performance is troubling, with a five-year return of -64.38% compared to the S&P 500's 96.61%. This suggests that while there may be short-term gains, the overall outlook remains bleak, reinforcing the view that the stock is overvalued.

Is Wave Life Sciences Ltd. technically bullish or bearish?

As of October 31, 2025, Wave Life Sciences Ltd. shows a neutral technical trend with mixed signals, indicating a cautious approach, as it has outperformed the S&P 500 recently but significantly underperformed year-to-date and over the past year.

As of 31 October 2025, the technical trend for Wave Life Sciences Ltd. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly chart. The Bollinger Bands indicate a mildly bullish trend weekly, while monthly data is bearish. Moving averages are mildly bearish on the daily timeframe. KST is bearish weekly and mildly bearish monthly, while Dow Theory shows no trend in both weekly and monthly perspectives. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 5.12% and 12.03% respectively, but has significantly underperformed year-to-date and over the past year, with returns of -35.25% and -42.08%. Overall, the technical indicators suggest a cautious approach given the mixed signals and the recent trend change to sideways.